Zydus Cadila collaborates with German researcher Pieris1 min read . Updated: 16 Oct 2013, 11:56 PM IST
Firms have signed a research alliance to develop and sell multiple anticalin protein therapeutics
Mumbai: Cadila Healthcare Ltd and German biopharmaceutical company Pieris AG have signed a research alliance to develop and sell multiple anticalin protein therapeutics, a new class of drugs that can be used for the treatment of a variety of disorders.
Cadila Health, also known as Zydus Cadila, said on Wednesday that the collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertize in biologics development, regulatory affairs and biologics manufacturing.
Zydus will have the exclusive marketing rights in India and several other emerging markets for the product, while Pieris retains exclusive marketing rights in key developed markets including the US and Europe.
“Collaborating with established biotech companies on differentiated drug candidates is an important component of Zydus’ ongoing transformation into an innovation-led global healthcare provider; we are pleased to add anticalins to our novel biological pipeline," Pankaj R. Patel, chairman and managing director of Zydus group, said in a statement.
“This collaboration will allow Pieris to unlock value on a global scale in a cost-effective manner, significantly expanding the number of propriety anticalin programmes we can advance into clinical trials." said Stephen Yoder, chief executive officer of Pieris.
Pieris has a similar agreement with Japan’s Daiichi Sankyo Co. Ltd, French drugmaker Sanofi SA, and US drugmaker Allergan Inc. on anticalin. Through this unique collaborative model, the companies seek to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris’ territories at the appropriate time, the release stated. The companies will share licensing revenue on mutually agreed terms.